Trial Profile
Docetaxel versus Docetaxel and Lapatinib in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). An open label multicenter randomized phase II study. A study of the Dutch Head and Neck Cancer Group (DHNCG) (NWHHT 08-02).
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Jul 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Lapatinib (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- Acronyms TyvTax study
- 29 Sep 2010 New trial record